Papers by Hagop M. Kantarjian
Page 11 · newest first
- Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.Journal of Clinical Oncology · 2018
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II studyHaematologica · 2018
- Cancer research in the United States: A critical review of current status and proposal for alternative modelsCancer · 2018
- MYC protein expression is an important prognostic factor in acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2018
- Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphomaCancer · 2018
- Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemiaCancer · 2018
- Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersBritish Journal of Cancer · 2018
- Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab OzogamicinAmerican Society of Clinical Oncology Educational Book · 2018
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaJournal of Clinical Oncology · 2018
- Final results of a phase 2, open‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndromeCancer · 2018
- Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Cancer · 2018
- Improving the detection of patients with inherited predispositions to hematologic malignancies using next‐generation sequencing‐based leukemia prognostication panelsCancer · 2018
- The importance of greater speed in drug development for advanced malignanciesCancer Medicine · 2018
- Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F MutationsThe American Journal of Surgical Pathology · 2018
- Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialBlood · 2018
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosisJournal of Hematology & Oncology · 2018
- Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemiaCancer · 2018
- Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDSClinical Cancer Research · 2018
- TH1/17 hybrid CD4+ cells in bronchial alveolar lavage fluid from leukemia patients with checkpoint inhibitor-induced pneumonitis.Journal of Clinical Oncology · 2018
- Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringAmerican Journal of Hematology · 2018
- Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATECancer · 2018
- Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideBlood · 2018
- Outcomes with lower intensity therapy in TP53 -mutated acute myeloid leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2018
- The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatmentCA A Cancer Journal for Clinicians · 2018
- Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasmsOncotarget · 2018
- A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid LeukemiaActa Haematologica · 2018
- Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phaseCancer · 2017
- Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosisEuropean Journal Of Haematology · 2017
- Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesAmerican Journal of Hematology · 2017
- Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapyBlood Advances · 2017
- Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careBlood Cancer Journal · 2017
- Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid LeukemiaBlood · 2017
- Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AMLBlood · 2017
- Outcomes By Treatment Setting and Genomic Profile in Patients with AML on Cladribine, Idarubicin, and CytarabineBlood · 2017
- Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemiaCancer · 2017
- Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primatesView · 2017
- Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitorsCurrent Opinion in Hematology · 2017
- Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionAmerican Journal of Hematology · 2017
- The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabBritish Journal of Haematology · 2017
- A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasmsAmerican Journal of Hematology · 2017
- Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)Experimental Hematology and Oncology · 2017
- Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activitiesOncotarget · 2017
- Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapyCancer · 2017
- Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphomaAmerican Journal of Hematology · 2017
- High-throughput single-cell DNA sequencing of AML tumors with droplet microfluidics2017
- Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitorsAmerican Journal of Hematology · 2017
- Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adultsAmerican Journal of Hematology · 2017
- Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingLeukemia & lymphoma/Leukemia and lymphoma · 2017
- PET-CT in AML-related hemophagocytic lymphohistiocytosisLeukemia & lymphoma/Leukemia and lymphoma · 2017
- Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemiaJournal of Cutaneous Pathology · 2017